Traders purchased shares of Illumina, Inc. (NASDAQ:ILMN) on weakness during trading hours on Thursday. $50.89 million flowed into the stock on the tick-up and $37.86 million flowed out of the stock on the tick-down, for a money net flow of $13.03 million into the stock. Of all equities tracked, Illumina had the 31st highest net in-flow for the day. Illumina traded down ($2.55) for the day and closed at $240.04

ILMN has been the subject of a number of research reports. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price for the company in a report on Friday, October 27th. Deutsche Bank raised Illumina from a “hold” rating to a “buy” rating and dropped their target price for the stock from $195.00 to $160.00 in a report on Monday, October 23rd. Canaccord Genuity reissued a “buy” rating and set a $230.00 target price (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. Vetr upgraded Illumina from a “hold” rating to a “buy” rating and set a $217.50 price target on the stock in a research report on Tuesday, September 19th. Finally, Bank of America raised their price target on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $214.38.

The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $35,730.00, a PE ratio of 46.17, a PEG ratio of 3.23 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same quarter in the previous year, the business posted $0.97 earnings per share. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. sell-side analysts expect that Illumina, Inc. will post 3.76 earnings per share for the current year.

In other news, EVP Omead Ostadan sold 3,540 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $226.91, for a total transaction of $803,261.40. Following the sale, the executive vice president now directly owns 26,827 shares in the company, valued at $6,087,314.57. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $217.38, for a total value of $271,725.00. Following the sale, the director now owns 8,838 shares in the company, valued at $1,921,204.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 137,671 shares of company stock worth $29,485,768. Company insiders own 0.89% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ILMN. Advisory Services Network LLC grew its holdings in shares of Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the last quarter. Dupont Capital Management Corp bought a new stake in shares of Illumina during the third quarter worth about $153,000. Patten Group Inc. grew its holdings in shares of Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock worth $172,000 after purchasing an additional 615 shares during the last quarter. West Coast Financial LLC bought a new stake in shares of Illumina during the third quarter worth about $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Illumina during the second quarter worth about $226,000. Institutional investors own 91.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/traders-buy-shares-of-illumina-ilmn-on-weakness/1805756.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.